A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
Status:
Recruiting
Trial end date:
2023-08-19
Target enrollment:
Participant gender:
Summary
This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular
Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved
liver function and without significant fibrosis/cirrhosis. The platform design allows
comparison of multiple NME combination therapies against a common control, and introduction
of additional treatment arms at later study time points. Each arm will consist of a screening
phase (up to 8 weeks), treatment phase (up to 48 weeks) and post-treatment follow-up phase
(48 weeks). The safety and efficacy will be monitored throughout the study.